Detail akcie Lunai Bioworks Rg online

Business Summary: Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Financial Summary: BRIEF: For the three months ended 30 September 2025, Lunai Bioworks Inc revenues was not reported. Net income totaled $2.8M vs. loss of $44.2M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.82 to $0.13.